A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-small cell lung cancer
MB12-C-02-24
Phase 3 other active
Quick answer
A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-small cell lung cancer for advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) is a Phase 3 program (other) at Mabxience Research SL with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Mabxience Research SL
- Indication
- advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)
- Phase
- Phase 3
- Modality
- other
- Status
- active